Key Insights:
- Dr. Benjamin Schlechter and Dr. Pashtoon Kasi discuss the evolving use of circulating tumor DNA (ctDNA) in diagnosing and managing colorectal cancer. ctDNA, often referred to as liquid biopsy, is gaining prominence for its ability to detect cancer presence and recurrence at a microscopic level, providing a non-invasive alternative to tissue biopsies.
- The discussion includes insights from significant clinical trials like BESPOKE and GALAXY, which demonstrate the utility of ctDNA in early-stage disease management. These studies have shown that ctDNA can be an effective tool in monitoring minimal residual disease (MRD) and guiding adjuvant chemotherapy decisions.
- The conversation highlights how ctDNA testing could revolutionize treatment strategies by allowing more personalized treatment approaches, such as adjusting chemotherapy based on ctDNA results. This capability could lead to de-escalation or escalation of treatment, potentially improving patient outcomes and reducing unnecessary treatments.